Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Yoon Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael L. Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason Paik, Amit Agarwal, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2023-180109

Published: 2023

Journal Articles

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Teng Liu, Erica Rappold, Peter Langmuir, Armando Lopez-Guillermo

Blood (2022) 140 (Supplement 1): 9328–9330.

https://doi.org/10.1182/blood-2022-159703

Published: 2022

Journal Articles

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D. Soumerai, Catherine S. Diefenbach, Felipe Samaniego, Abhijeet Kumar, Michaela L. Tsai, Adam S. Asch, Deepa Jagadeesh, Vaishalee P. Kenkre, Izidore S. Lossos, Huda Salman, Farrukh T. Awan, Lu Miao, Richard G. Ghalie, Andrew D. Zelenetz

Blood (2022) 140 (Supplement 1): 189–191.

https://doi.org/10.1182/blood-2022-157563

Published: 2022

Journal Articles

Anti-CD 19 CAR-T Cell Therapy with Tisagenlecleucel for Ritcher Syndrome

Iloabueke Chineke, Muhammad Hassab, Abhijeet Kumar, Muhammad Husnain

Blood (2022) 140 (Supplement 1): 12796–12797.

https://doi.org/10.1182/blood-2022-167450

Published: 2022

Journal Articles

A First-in-Human Phase 1 Dose Escalation and Expansion Study of the Oral CARD11-BCL10-MALT1 Signaling Pathway Inhibitor XL114 in Patients with Non-Hodgkin's Lymphoma

Bert H. O'Neil, Willy Solis, Sofia Vidal-Cardenas, Shailaja Uttamsingh, Abhijeet Kumar

Blood (2022) 140 (Supplement 1): 12055–12056.

https://doi.org/10.1182/blood-2022-167824

Published: 2022

Journal Articles

Anti CD19 CAR-T Cell Therapy Can Clear Minimal Residual Disease in Bone Marrow of Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphomas

Armaan Dhaliwal, Mahima Zandu, Sharad Khurana, Abhijeet Kumar, Jeffrey J. Pu, Emmanuel Katsanis, Muhammad Husnain

Blood (2022) 140 (Supplement 1): 12760–12761.

https://doi.org/10.1182/blood-2022-170620

Published: 2022

Journal Articles

Role of Anakinra in the Management of Steroid Refractory High Grade Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after Anti-CD 19 CAR-T Cell Therapy, a Single Center Experience

Ulyana Dashkevych, Nishant Munugala, Sharad Khurana, Abhijeet Kumar, Krisstina L. Gowin, Akshay Amaraneni, Ravi Krishnadasan, Jeffrey J. Pu, Emmanuel Katsanis, Muhammad Husnain

Blood (2022) 140 (Supplement 1): 12753–12754.

https://doi.org/10.1182/blood-2022-168240

Published: 2022

Journal Articles

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Trace Bartels, BS, Logan Moore, Neda Alrawashdh, PharmD, Abhijeet Kumar, Ivo Abraham, PhD RN, Daniel O. Persky, MD, Ali McBride, PharmD, MS

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-141651

Published: 2020

Journal Articles

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Logan Moore, Trace Bartels, BS, Daniel O. Persky, MD, Abhijeet Kumar, Ivo Abraham, PhD RN, Lauren Sanders, PharmD, Alicia Ortega, PharmD, Alyssa Henglefelt, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 5353.

https://doi.org/10.1182/blood-2019-132148

Published: 2019

Journal Articles

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, Mok Oh, Daniel Persky, MD, Faiz Anwer, MD, Leslie Andritsos, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4678.

https://doi.org/10.1182/blood.V130.Suppl_1.4678.4678

Published: 2017

Journal Articles

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, HyunJung Kim, Mok Oh, Leslie Andritsos, MD, Faiz Anwer, MD, Daniel Persky, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4679.

https://doi.org/10.1182/blood.V130.Suppl_1.4679.4679

Published: 2017

Journal Articles

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Abhijeet Kumar, MD, Jose Guillen-Rodriguez, Jonathan H. Schatz, MD, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, MD, Faiz Anwer, MD, Daruka Mahadevan, MD PhD, Daniel O. Persky, MD, Soham D. Puvvada, MD

Blood (2016) 128 (22): 1790.

https://doi.org/10.1182/blood.V128.22.1790.1790

Published: 2016

Journal Articles

Mantle cell lymphoma presenting as cardiac tamponade

Abhijeet Kumar, Soham Puvvada

Blood (2015) 126 (10): 1255.

https://doi.org/10.1182/blood-2015-03-626051

Published: 2015

NARROW

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Anti-CD 19 CAR-T Cell Therapy with Tisagenlecleucel for Ritcher Syndrome

A First-in-Human Phase 1 Dose Escalation and Expansion Study of the Oral CARD11-BCL10-MALT1 Signaling Pathway Inhibitor XL114 in Patients with Non-Hodgkin's Lymphoma

Anti CD19 CAR-T Cell Therapy Can Clear Minimal Residual Disease in Bone Marrow of Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphomas

Role of Anakinra in the Management of Steroid Refractory High Grade Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after Anti-CD 19 CAR-T Cell Therapy, a Single Center Experience

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Mantle cell lymphoma presenting as cardiac tamponade

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only